Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis

Belal Firwana, MD, Mohamad Bassam Sonbol, MD, Shebli Atrash, MD, Rahul Ravilla, MD, Mihir Raval, MD MPH, Lin Hao, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Muthu Veeraputhiran, MD MPH, Issam Makhoul, MD, Appalanaidu Sasapu, MD MS

Blood (2016) 128 (22): 5594.

https://doi.org/10.1182/blood.V128.22.5594.5594

Published: 2016

Journal Articles

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Sharmilan Thanendrarajan, MD, Caleb K. Stein, MS, Faith E Davies, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Carolina Schinke, MD, Sarah Waheed, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Niels Weinhold, PhD, Aasiya Matin, Pankaj Mathur, Meera Mohan, Muthukumar Radhakrishnan, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 3182.

https://doi.org/10.1182/blood.V126.23.3182.3182

Published: 2015

Journal Articles

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

Sarah Waheed, MD, Hongwei Wang, Pingping Qu, PhD, Christoph Heuck, MD, Aasiya Matin, Yogesh Jethava, MB, MRCP, MD FRCPath, Frits van Rhee, MD PhD, Antje Hoering, Bart Barlogie, MD PhD, Faith E Davies, MD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1777.

https://doi.org/10.1182/blood.V126.23.1777.1777

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Alan Mitchell, Donald Johann, MD MS, Kelly Robbins, Ryan K Van Laar, PhD, Siraj Ali, MDPhD, Vincent A. Miller, MD, Clyde Bailey, Jeffery Sawyer, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD, PhD

Blood (2014) 124 (21): 4775.

https://doi.org/10.1182/blood.V124.21.4775.4775

Published: 2014

Journal Articles

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Yogesh Jethava, MB, MRCP, MD FRCPath, Rachel Hunter-Merrill, Gareth J Morgan, MD PhD, Rashid Z Khan, MD, Aasiya Matin, MD, Christoph Heuck, MD, Maurizio Zangari, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3407.

https://doi.org/10.1182/blood.V124.21.3407.3407

Published: 2014

Journal Articles

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Maurizio Zangari, MD, Caleb K Stein, MS, Shmuel Yaccoby, PhD, Donghoon Yoon, PhD, Christoph Heuck, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Donald Johann, MD MS, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Frits van Rhee, MD PhD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3409.

https://doi.org/10.1182/blood.V124.21.3409.3409

Published: 2014

Journal Articles

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Christoph Heuck, MD, Donald Johann, MD MS, Brian A Walker, PhD, Caleb K Stein, MS, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Scott Miller, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Ruslana Tytarenko, Phillip Farmer, Ryan Williams, Siraj Ali, MDPhD, Phil J Stephens, PhD, Vincent A. Miller, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3418.

https://doi.org/10.1182/blood.V124.21.3418.3418

Published: 2014

Journal Articles

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Rashid Z Khan, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Xenofon Papanikolaou, MD, Caleb K Stein, MS, Adam Rosenthal, Christoph Heuck, MD, Frits van Rhee, MD PhD, Jameel Muzaffar, MD, Maurizio Zangari, MD, Clyde Bailey, Phillip Farmer, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5770.

https://doi.org/10.1182/blood.V124.21.5770.5770

Published: 2014

Journal Articles

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Xenofon Papanikolaou, MD, Rashid Z Khan, MD, Adam Rosenthal, Clyde Bailey, Yogesh Jethava, MB, MRCP, MD FRCPath, Christoph Heuck, MD, Susan B. Panozzo, BS, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Carolina Schinke, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2128.

https://doi.org/10.1182/blood.V124.21.2128.2128

Published: 2014

Journal Articles

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Bounleut Phanavanh, Priyangi Malaviarachchi, Adam Rosenthal, Yogesh Jethava, MB, MRCP, MD FRCPath, Bart Barlogie, MD PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Sarah K. Johnson, PhD

Blood (2014) 124 (21): 2012.

https://doi.org/10.1182/blood.V124.21.2012.2012

Published: 2014

Journal Articles

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Frits van Rhee, MD PhD, Alan Mitchell, Christoph Heuck, MD, Monica Grazziutti, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Rashid Z Khan, MD, Donald Johann, MD MS, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 1199.

https://doi.org/10.1182/blood.V124.21.1199.1199

Published: 2014

Journal Articles

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenofon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD PhD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2078.

https://doi.org/10.1182/blood.V124.21.2078.2078

Published: 2014

Journal Articles

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Xenofon Papanikolaou, MD, Adam Rosenthal, Rashid Z Khan, MD, Joshua Epstein, DSc, Christoph Heuck, MD, Madhav V. Dhodapkar, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Omar Atiq, MD, Sarah Waheed, MD, Faith Davies, MD, Gareth J Morgan, MD PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2079.

https://doi.org/10.1182/blood.V124.21.2079.2079

Published: 2014

Journal Articles

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

Anjum Bashir Khan, MBChB, MRCP, Donal McLornan, MD, PhD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Kavita Raj, MD, PhD, MRCP, FRCPath, Victoria T Potter, MBBS, FRCPA, FRACP, Hugues de Lavallade, MD, Majid A Kazmi, BmedBiol MB ChB MRCP (UK) MRCPath, ZiYi Lim, MD, Judith C. W. Marsh, Prof MD PhD, Sangeeta Atwal, MBBS MRCP FRCPath, Victor Noriega, MD, Claire N Harrison, DM FRCP FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4532.

https://doi.org/10.1182/blood.V120.21.4532.4532

Published: 2012

Journal Articles

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Sangeeta Atwal, MBBS, MRCP, FRCPath, Anjum Bashir Khan, MBChB, MRCP, Victor Noriega, MD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Michelle Kenyon, BSc, RN, Hugues de Lavallade, MD, Donal McLornan, MD, PhD, Victoria T Potter, MBBS, FRCPA, FRACP, Kavita Raj, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4216.

https://doi.org/10.1182/blood.V120.21.4216.4216

Published: 2012

NARROW

Efficacy of First-Line CLL Treatments in Comparison to Chlorambucil: A Network Meta-Analysis

Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials

Gene Expression Profiling of Extramedullary Disease-Related Toward Identification of a Terminal Disease Pathway in Multiple Myeloma

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma

PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients

Higher Expressions of PTH Receptor Type 1 and/or 2 in Bone Marrow Is Associated to Longer Survival in Newly Diagnosed Myeloma Patients Enrolled in Total Therapy 3

Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling

Low-Dose 28-Day Metronomically Scheduled Therapy (METRO) for Newly Diagnosed High-Risk Multiple Myeloma: A Pilot Study

Further Evolution of Metronomic Therapy Extended to 28 Days (Metro28) for Relapsed Refractory Multiple Myeloma (RRMM)

Low BCL11A Expression in the Myeloma Microenvironment at Diagnosis Is Associated with Early Development of MDS Cytogenetic Abnormalities and Poor Overall Survival

Total Therapy 4 (TT4) for GEP70-Defined Low Risk Clinical Multiple Myeloma (CMM): Results of Patients Randomized to a Standard v Light Rrm (S-TT4 v L-TT4)

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Flow Cytometry Defined Cytoplasmic Immunoglobulin Index Is a Major Prognostic Factor for Progression of Asymptomatic Monoclonal Gammopathies to Clinical Multiple Myeloma

Allogeneic Stem Cell Transplantation for Accelerated/Blastic Phase Philadelphia-Chromosome Negative MPN

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only